Japan Flu Diagnostic and Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

Description

Japan Flu Diagnostic and Treatment Market Size:

Japan Flu Diagnostic and Treatment Market is projected to grow considerably during the forecast period (2025-2030).

To learn more about this report, request a free sample copy

The Japanese Flu Diagnostic and Treatment Market operates within one of the world's most unique and regulated healthcare environments, where demographic pressure and a proactive, government-backed infectious disease surveillance network define commercial activity. Unlike other developed markets, Japan’s strategy relies heavily on immediate, point-of-care diagnosis paired with an expansive portfolio of reimbursed antivirals. This regulatory and clinical mandate transforms annual influenza outbreaks into predictable, high-volume demand cycles for diagnostic kit consumables and prescribed therapeutics. The recent severe and early flu seasons in 2024 and 2025 have strained the outpatient clinic capacity, encouraging providers to rapidly implement high-throughput diagnostic platforms to facilitate timely treatment initiation and manage the escalating patient burden, especially among the highly vulnerable geriatric segment.

Japan Flu Diagnostic and Treatment Market Analysis

• Growth Drivers

The primary catalyst propelling the market is the nation’s advanced geriatric demographic structure. The population aged ≥ 65 years presents a persistently high risk of influenza-related complications, driving demand for both prophylactic drugs and intensive therapeutic regimens. Second, the national reimbursement policy for immediate antiviral administration, contingent upon a rapid positive diagnosis within 48 hours of symptom onset, structurally ensures that every diagnosed case of influenza immediately translates into a prescription for a therapeutic agent. This policy accelerates the purchasing cycle for both Diagnostics and Therapeutics. Furthermore, the persistent and increasing threat of antiviral resistance requires clinicians to maintain a diverse formulary and shift to newer mechanistic classes like cap-dependent endonuclease inhibitors, continuously renewing the therapeutic product demand.

• Challenges and Opportunities

The primary challenge is the supply chain vulnerability for active pharmaceutical ingredients (APIs) and diagnostic kit components, which can experience immediate constraints during a severe or early epidemic, directly limiting the available volume of diagnostics and therapeutics. Another constraint is the staffing and facility capacity of outpatient clinics to handle the surge in ILI cases, which can hinder patient throughput and limit diagnostic testing volume. This constraint concurrently creates a significant opportunity for Point-of-Care (POC) molecular assays that offer high diagnostic accuracy without the logistical burden of central laboratory processing, thereby expanding testing access outside of major hospitals. A further opportunity lies in the development of multi-analyte panels that can simultaneously differentiate between Flu A, Flu B, and other endemic respiratory viruses, streamlining differential diagnosis and preserving therapeutic efficacy through precision prescribing.

• Raw Material and Pricing Analysis

The Japanese Flu Diagnostic and Treatment Market is fundamentally a physical product market, encompassing both in-vitro diagnostic kits and anti-influenza pharmaceuticals. Diagnostic kit manufacturers are highly dependent on globally sourced biochemical reagents (e.g., antibodies, primers, probes) and polymer materials for cartridge manufacturing. Price volatility in these raw materials, driven by global supply chain disruptions, directly impacts the cost of goods sold for Rapid Influenza Diagnostic Tests (RIDTs) and Rapid Molecular Assays. Therapeutic pricing is rigidly controlled by the National Health Insurance (NHI) drug price revision mechanism, which mandates biennial price cuts for most branded pharmaceuticals, including antivirals like oseltamivir and baloxavir marboxil. This regulatory pricing pressure constrains profit margins for drug companies, compelling them to invest in next-generation molecules or high-volume generic production to maintain market share.

• Supply Chain Analysis

The supply chain is vertically integrated for pharmaceuticals and highly distributed for diagnostics. Therapeutic agents, particularly Neuraminidase Inhibitors and newer molecules, are predominantly manufactured by multinational or major domestic firms (e.g., Chugai, Shionogi) and distributed through a consolidated network of Japanese wholesalers, ensuring reliable stockpiling under government mandate. In contrast, the diagnostic segment features high-volume kits supplied by international companies (e.g., Abbott, BD, Quidel), which depend on global production hubs, creating logistical complexities. The primary dependency is on the Ministry of Health, Labour and Welfare (MHLW)'s annual influenza surveillance data, which dictates the volume and timing of wholesaler orders. Logistical bottlenecks occur not at the national level, but at the last mile, the ability of smaller outpatient clinics to maintain adequate, temperature-controlled inventory for an unexpectedly severe, early season.

Japan Flu Diagnostic and Treatment Market Government Regulations

Government policy in Japan serves as the paramount determinant of market expansion, specifically through its mandatory surveillance and reimbursement rules.

Japan Flu Diagnostic and Treatment Market Segment Analysis

• By Offering: Rapid Influenza Diagnostic Test

The Rapid Influenza Diagnostic Test (RIDT) segment remains the bedrock of the Japanese diagnostic market, characterized by its ubiquity in the Outpatient Clinic setting. This expansion is intrinsically tied to the MHLW’s clinical guidelines, which prioritize timely diagnosis to initiate antiviral therapy within the critical 48-hour window. The primary growth driver is the cost-effectiveness and ease of use of RIDTs. Clinicians, especially in smaller clinics, favor RIDTs for their rapid result delivery (typically under 15 minutes) and minimal instrumentation requirement, enabling efficient patient triage during seasonal peaks. However, the post-pandemic environment is shifting demand towards higher sensitivity and specificity tests. The lowered population immunity observed in the 2024-2025 season created a higher-volume testing scenario, but the desire to reduce false negatives, especially in high-risk patients, is a powerful long-term driver for the transition to more accurate Rapid Molecular Assays (RMAs). The vast network of Japanese clinics, however, ensures the high-volume consumption of the established RIDT platform for basic screening.

• By Age Group: ≥ 65 Years

The cohort aged ≥ 65 years is the most critical demand segment for the entire market, disproportionately driving consumption across both the Diagnostic and Therapeutic categories. This segment’s key growth driver is their elevated clinical vulnerability and higher rate of complications (e.g., pneumonia, hospitalization), making immediate and accurate diagnosis a life-saving imperative. Consequently, this demographic generates demand for more sensitive testing methods (RMAs over RIDTs) and mandatory post-exposure prophylaxis. The NHI's comprehensive coverage for high-risk patients ensures that economic constraints do not inhibit prescribing behavior. Furthermore, this cohort is the primary recipient of the four distinct MHLW-approved antiviral drugs (oseltamivir, zanamivir, peramivir, baloxavir marboxil), often requiring a switch in treatment based on local resistance profiles or concomitant conditions. This combination of demographic growth, clinical vulnerability, and robust reimbursement guarantees high and non-discretionary demand for both diagnostic confirmation and therapeutic intervention.

Japan Flu Diagnostic and Treatment Market Competitive Environment and Analysis

The Japanese Flu Diagnostic and Treatment market features a competitive duality, split between dominant domestic pharmaceutical firms specializing in therapeutics and powerful global medical technology companies leading the diagnostics space. Competition is primarily focused on product sensitivity/speed in diagnostics and mechanism of action/resistance profile in therapeutics.

Japan Flu Diagnostic and Treatment Market Company Profiles

• Chugai Pharmaceutical Co., Ltd

Chugai, a member of the Roche Group, focuses on the therapeutic segment. While they distribute Roche's anti-influenza drug Tamiflu (oseltamivir), their strategic positioning is centered on highly specialized oncology and specialty therapeutics, with influenza being a foundational component of their infectious disease portfolio. The company's competitive advantage in this market stems from its long-established logistical network for drug distribution and its intrinsic connection to a globally relevant pipeline. Their verified product positioning ensures high-volume sales of a standard-of-care antiviral, capitalizing on the government's mandatory stockpiling and national drug distribution strategy.

• Abbott

Abbott strategically targets the shift toward rapid, molecular point-of-care (POC) testing, positioning itself as a leader in advanced diagnostics. Their key product, the ID NOW™ Influenza A & B 2 assay, uses isothermal nucleic acid amplification technology (NAAT) to deliver molecular results in minutes. This technology directly addresses the demand imperative for speed and accuracy in outpatient clinics that must meet the MHLW's 48-hour treatment window. Abbott's competitive strategy involves capitalizing on the need for high-fidelity diagnostics that bridge the gap between low-sensitivity RIDTs and time-consuming central lab PCR, thereby enabling definitive clinical decisions at the point of patient encounter.

• Quidel Corporation

Quidel (now QuidelOrtho) is a prominent force in the traditional Rapid Influenza Diagnostic Test (RIDT) and fluorescent immunoassay (FIA) segments, particularly with their Sofia® 2 Fluorescent Immunoassay (FIA) platform. Their strategic positioning is high-volume penetration of outpatient and hospital laboratories by offering a fast, instrument-read, semi-automated platform. The Sofia platform is designed for ease of use and objective interpretation, making it highly effective for rapid deployment in high-patient-volume settings like hospital emergency rooms and large outpatient clinics during seasonal peaks. The company maintains its market presence by balancing speed with accuracy improvements over visual-read RIDTs.

Japan Flu Diagnostic and Treatment Market Developments

• September 2024: Roche announced positive topline results from the Phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), demonstrating a reduction in influenza transmission within households. This finding, originating from the global partner of the drug that dominates the newer therapeutic segment, serves as a significant market development, promoting the drug's use for post-exposure prophylaxis and potentially broadening its strategic market positioning beyond initial acute treatment.

• February 2024: Quidel Corporation initiated a Class 2 device recall (Lot 709083) for the Sofia 2 Flu + SARS Antigen FIA due to incorrect expiration dates on the kit components. This mandatory correction event directly impacted product inventory and distribution channels for a crucial diagnostic product at the point of care, temporarily constraining product availability and highlighting the fragility of supply chain logistics during peak flu season.

Japan Flu Diagnostic and Treatment Market Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory

Table Of Contents

1. Introduction
1.1. Market Overview
1.2. Scope of the Study
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Japan Flu Diagnostic and Treatment Market Analysis, By Type of Flu
5.1. Introduction
5.2. Type A
5.3. Type B

6. Japan Flu Diagnostic and Treatment Market Analysis, By Offering
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics

7. Japan Flu Diagnostic and Treatment Market Analysis, By Age Group
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years

8. Japan Flu Diagnostic and Treatment Market Analysis, By End-User 
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory

9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. Company Profiles
10.1. Abbott
10.2. Chugai Pharmaceutical Co., Ltd
10.3. BD
10.4. Thermo Fisher Scientific
10.5. 3M
10.6. Quidel Corporation

Companies Profiled

Abbott

Chugai Pharmaceutical Co., Ltd

BD

Thermo Fisher Scientific

3M

Quidel Corporation

Related Reports